Listed

Nutex Health Inc.: Form 10-Q for the period ended Jun 30, 2018

Filed with the SEC on Aug 14, 2018 and accepted by EDGAR at Aug 14, 2018, 14:54 ET.

Share

Management's discussion and analysis

As filed, 15,495 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

FORWARD LOOKING STATEMENTS

This Form 10-Q includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, included or incorporated by reference in this Form 10-Q which address activities, events or developments that the Company expects or anticipates will or may occur in the future, including such things as future capital expenditures (including the amount and nature thereof), finding suitable merger or acquisition candidates, expansion and growth of the Company’s business and operations, and other such matters are forward-looking statements. These statements are based on certain assumptions and analyses made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments as well as other factors it believes are appropriate in the circumstances.

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve significant risks and uncertainties, and that actual results may differ materially from those projected in the forward-looking statements. Factors that could adversely affect actual results and performance include, among others, potential fluctuations in quarterly operating results and expenses, government regulation, technology change and competition. Consequently, all of the forward-looking statements made in this Form 10-Q are qualified by these cautionary statements and there can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequence to or effects on the Company or its business or operations. The Company assumes no obligations to update any such forward-looking statements.

INTRODUCTION

iGambit is a company focused on the medical technology markets. Our primary focus is the expansion of our newly acquired medical technology business HealthDatix Inc.

HealthDatix is an end to end Software-as-a-Service solution that manages, reports, and analyzes critical data, enabling healthcare organizations to deliver positive patient outcomes. HealthDatix provides an opportunity for physicians to identify patients eligible for both “Annual Wellness Visits” (AWV) as well as “Chronic Care Management” both of which are reimbursed by Medicare.

Our AWV solution offers a fully-hosted cloud service for healthcare providers to conduct the Medicare Annual Wellness Visit (AWV) program to their Medicare patients providing the patient with a 5-10 year Personalized Preventive Plan and physician reports that meet all Medicare audit requirements. The AWV is a program that allows a physician to identify those patients that have 2+ chronic conditions that require additional screening and management.

Additionally our Chronic Care Management System (CCM), encompasses our FDA approved Electronic House Call system and Medicare covered platform, for continuous management of chronic care patients. The CCM platform can be tailored for individual care and health management of patients susceptible to chronic illness. The CCM platform is also designed to accumulate information from our BioDatix HealthBand, or any TeleMedicine or wearable device.

The BioDatix Health Band pilot launch for September 2018 will provide the ability to passively collect a wearers Heart Rate, Blood Oxygen, Blood Pressure, Sleep and Steps/Distance/Calories.

The data is then transmitted to our CCM back-end application producing trend reports and alerts. Identified “out of limit” or “unusual” baselines that can be managed by the wearer, caregiver, physicians and physicians’ staff.

Assets. At June 30, 2018, we had $2,982,581 in total assets, compared to $3,328,755 at December 31, 2017. The decrease in total assets was primarily due to amortization of intangible assets from the acquisition of our HealthDatix subsidiary.

Liabilities. At June 30, 2018, our total liabilities were $1,117,168 compared to $959,780 at December 31, 2017. Our current liabilities at June 30, 2018 consisted of accounts payable and accrued expenses of 290,141, accrued interest on notes payable of $27,420, amounts due to related parties of $128,476, deferred revenue of $1,650, notes payable of $52,500, convertible debentures of $583,508, and derivative liability of $33,473, whereas our current liabilities at December 31, 2017 consisted of accounts payable and accrued expenses of $348,354, accrued interest on notes payable of $21,602, amounts due to related parties of $128,476, deferred revenue of $9,100, notes payable of $52,500, convertible debentures of $333,689, and derivative liability of $66,059.

Stockholders’ Equity. Our Stockholders’ Equity was $1,865,413 at June 30, 2018 compared to Stockholders Equity of $2,368,975 at December 31, 2017. This decrease was primarily due to an increase in accumulated deficit during the six months ended June 30, 2018.

three Months Ended JUNE 30, 2018 as Compared to Three Months Ended JUNE 30, 2017

Revenues and Net Loss. We had $3,726 of revenue from our HealthDatix subsidiary and a net loss of $726,247 during the three months ended June 30, 2018, compared to $4,595 of revenue and a net loss of $1,647,250 during the three months ended June 30, 2017. The decrease in revenue was due primarily to revenue generated by our HealthDatix subsidiary.

General and Administrative Expenses. General and Administrative Expenses decreased to $310,873 from $913,213 for the three months ended June 30, 2018 from the three months ended June 30, 2017. For the three months ended June 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $24,175, depreciation expense of $432, legal and accounting fees of $26,500, employee benefits expenses (health and life insurance) of $11,623, marketing expense of $17,941, travel expenses of $3,859, payroll expenses of $103,344, contract labor expenses of $12,000, consulting fees expense of $89,400, exchange filing fees of $4,200, rent expense of $7,188, and transfer agent fees of $10,211. For the three months ended June 30, 2017 our General and Administrative Expenses consisted of corporate administrative expenses of $33,723, board compensation expenses of $133,856, legal and accounting fees of $74,200, employee benefits expenses (health and life insurance) of $16,916, marketing expenses of $17,053, payroll expenses of $383,910, commissions and fees expenses of $52,675, consulting fees expenses of $179,111, exchange filing fees of $3,717, rent expense of $7,052 and research and development Expense of 11,000. The decreases from the three months ended June 30, 2017 to the three months ended June 30, 2018 relate primarily due to: (i) a decrease in payroll expense and employee benefits, (ii) a decrease in board compensation expenses, and (iii) a decrease in consulting and fees expenses. Costs associated with the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported a loss on change in fair value of derivative liability of $86,090, loss on extinguishment of debt of $74,571 and interest expense of $76,577 for the three months ended June 30, 2018. We reported loss on sale of subsidiary of $396,972 and interest expense of $1,738 for the three months ended June 30, 2017.

six Months Ended june 30, 2018 as Compared to six Months Ended june 30, 2017

Revenues and Net Loss. We had $7,918 of revenue from our HealthDatix subsidiary and a net loss of $1,336,280 during the six months ended June 30, 2018, compared to revenue of $8,945 and a net loss of $1,889,324 for the six months ended June 30, 2017. The decrease in revenue was due primarily to the revenue generated by our HealthDatix subsidiary. We reported a loss of $66,937 from discontinued operations for the six months ended June 30, 2017.

General and Administrative Expenses. General and Administrative Expenses decreased to $545,137 for the six months ended June 30, 2018 from $1,067,847 for the six months ended June 30, 2017. For the six months ended June 30, 2018 our General and Administrative Expenses consisted of corporate administrative expenses of $46,699, depreciation expense of $863, legal and accounting fees of $44,610, employee benefits expenses (health and life insurance) of $21,891, marketing expense of $34,616, trade show expense of $5,543, travel expenses of $4,965, payroll expenses of $208,430, contact labor expenses of $24,200, commissions and fees expense of $21,000, consulting fees expense of $89,400, exchange filing fees of $10,810, rent expense of $14,235, and transfer agent fees of $17,875. For the six months ended June 30, 2017 our General and Administrative Expenses consisted of corporate administrative expenses of $52,272, board compensation expense of $134,856, legal and accounting fees of $110,801, employee benefits expenses (health and life insurance) of $31,220, marketing expense of $33,719, payroll expenses of $418,393, commissions and fees expense of $64,475, consulting fees expense of $187,136, exchange filing fees of $11,333, rent expense of $12,642, and research and development expense of $11,000. The decreases from the six months ended June 30, 2017 to the six months ended June 30, 2018 relate primarily due to: (i) a decrease in payroll expense and employee benefits, (ii) a decrease in board compensation expenses, and (iii) a decrease consulting and fees expenses. Costs associated with the operation of our HealthDatix subsidiary are expected to increase going forward, as we expand the business operations of HealthDatix which would likely increase our corporate administrative expenses.

Other Income (Expense). We reported a loss on change in fair value of derivative liability of $204,191, loss on extinguishment of debt of $138,270 and interest expense of $92,841 for the six months ended June 30, 2018. We reported loss on sale of subsidiary of $396,972 and interest expense of $13,665 for the six months ended June 30, 2017.

Liquidity and Capital Resources

General

As reflected in the accompanying consolidated financial statements, at June 30, 2018, we had $50,917 of cash and stockholders’ equity of $1,865,413. At December 31, 2017, we had $9,449 of cash and stockholders’ equity of $2,368,975.

Our primary capital requirements in 2018 are likely to arise from the expansion of our HealthDatix operations. It is not possible to quantify those costs at this point in time, in that they depend on HealthDatix’s business opportunities and the state of the overall economy. We anticipate raising capital in the private markets to cover any such costs, though there can be no guaranty we will be able to do so on terms we deem to be acceptable. We do not have any plans at this point in time to obtain a line of credit or other loan facility from a commercial bank.

While we believe in the viability of our strategy to improve HealthDatix’s sales volume, and in our ability to raise additional funds, there can be no assurances that we will be able to fully effectuate our business plan.

We believe we will continue to increase our cash position and liquidity for the foreseeable future. We believe we have enough capital to fund our present operations.

Cash Flow Activity

Net cash used in operating activities was $492,032, for the six months ended June 30, 2018, compared to $367,692 for the six months ended June 30, 2017. Net cash used in continuing operating activities was $492,032 for the six months ended June 30, 2018, compared to $367,950 for the six months ended June 30, 2017. Our primary use of operating cash flows from continuing operating activities was from net losses of $1,336,280 and $1,889,324 for the six months ended June 30, 2018 and 2017, respectively. Additional contributing factors to the change were from depreciation expense of $863, amortization expense of $347,935, non-cash interest expense of $91,008, stock based compensation of $88,800, loss on the extinguishment of debt of $138,270, a change in fair value of derivative liability of $204,191, decrease in accounts receivable of $5,128, a decrease in prepaid expenses of $33,716, a decrease in accounts payable and accrued expenses of $58,213, and a decrease in deferred revenue of $7,450. Net cash provided by discontinued operations was $258 for the six months ended June 30, 2017. Cash provided by discontinued operations was primarily due to a decrease in accounts receivable from discontinued operations for the six months ended June 30, 2017.

Net cash used in continuing investing activities was $0 for the six months ended June 30, 2018 and $30,798 for the six months ended June 30, 2017. For the six months ended June 30, 2017 the primary use of cash flows in investing activities was pre-acquisition loans to subsidiaries and loans to our Arcmail subsidiary prior to deconsolidation.

Net Cash provided by financing activities was $533,500 for the six months ended June 30, 2018 compared to $391,492 for the six months ended June 30, 2017. The cash flows provided by continuing financing activities for the six months ended June 30, 2018 was primarily from $30,000 in proceeds from the sale of common stock and $503,500 in proceeds from issuance of convertible debentures. The cash flows provided by continuing financing activities for the six months ended June 30, 2017 was primarily from $175,000 in proceeds from the sale of common stock and $225,000 in proceeds from issuance of convertible debentures.

Plan of Operation and Funding

We expect that working capital requirements will continue to be funded through a combination of our existing funds and further issuances of securities. Our working capital requirements are expected to increase in line with the growth of our business. Existing working capital, further advances and debt instruments, and anticipated cash flow are expected to be adequate to fund our operations over the next twelve months. We have no lines of credit or other bank financing arrangements. Generally, we have financed operations to date through the proceeds of the private placement of equity and debt instruments. In connection with our business plan, management anticipates additional increases in operating expenses and capital expenditures relating to: (i) developmental expenses associated with a start-up business and (ii) marketing expenses. We intend to finance these expenses with further issuances of securities, and debt issuances. Thereafter, we expect we will need to raise additional capital and generate revenues to meet long-term operating requirements. Additional issuances of equity or convertible debt securities will result in dilution to our current shareholders. Further, such securities might have rights, preferences or privileges senior to our common stock. Additional financing may not be available upon acceptable terms, or at all. If adequate funds are not available or are not available on acceptable terms, we may not be able to take advantage of prospective new business endeavors or opportunities, which could significantly and materially restrict our business operations.

Controls and procedures

As filed, 1,906 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q.

Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of June 30, 2018, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting that occurred during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on Effectiveness of Controls and Procedures

In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2018-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2018-04-01 to 2018-06-30$3.7kus-gaap:Revenues
Revenue6 months2018-01-01 to 2018-06-30$7.9kus-gaap:Revenues
Cost of revenue3 months2018-04-01 to 2018-06-30$7.9kus-gaap:CostOfRevenue
Cost of revenue6 months2018-01-01 to 2018-06-30$15.8kus-gaap:CostOfRevenue
Gross profit3 months2018-04-01 to 2018-06-30−$4.2kus-gaap:GrossProfit
Gross profit6 months2018-01-01 to 2018-06-30−$7.9kus-gaap:GrossProfit
Operating income3 months2018-04-01 to 2018-06-30−$489.0kus-gaap:OperatingIncomeLoss
Operating income6 months2018-01-01 to 2018-06-30−$901.0kus-gaap:OperatingIncomeLoss
Interest expense3 months2018-04-01 to 2018-06-30$76.6kus-gaap:InterestExpense
Interest expense6 months2018-01-01 to 2018-06-30$92.8kus-gaap:InterestExpense
Net income3 months2018-04-01 to 2018-06-30−$726.2kus-gaap:NetIncomeLoss
Net income6 months2018-01-01 to 2018-06-30−$1.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2018-04-01 to 2018-06-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2018-01-01 to 2018-06-30−$0.01us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2018-01-01 to 2018-06-30−$492.0kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2018-06-30$50.9kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2018-06-30$57.7kus-gaap:AssetsCurrent
Total assetsAt period end2018-06-30$3.0mus-gaap:Assets
Current liabilitiesAt period end2018-06-30$1.1mus-gaap:LiabilitiesCurrent
Shareholders' equityAt period end2018-06-30$1.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001607062-18-000246. Last ingested by Listed: Nov 14, 2026, 12:46 ET. Listed shows no prices and gives no investment advice.